Allopurinol Sodium

Ingredient matches for Allopurinol Sodium

Allopurinol

Allopurinol sodium salt (a derivative of Allopurinol) is reported as an ingredient of Allopurinol Sodium in the following countries:

• United States

International Drug Name Search

Glempid

Glempid may be available in the countries listed below.

Ingredient matches for Glempid

Glimepiride

Glimepiride is reported as an ingredient of Glempid in the following countries:

• Bulgaria


• Hungary

International Drug Name Search

Finasterida Tecnigen

Finasterida Tecnigen may be available in the countries listed below.

Ingredient matches for Finasterida Tecnigen

Finasteride

Finasteride is reported as an ingredient of Finasterida Tecnigen in the following countries:

• Spain

International Drug Name Search

Benoxinat

Benoxinat may be available in the countries listed below.

Ingredient matches for Benoxinat

Oxybuprocaine

Oxybuprocaine hydrochloride (a derivative of Oxybuprocaine) is reported as an ingredient of Benoxinat in the following countries:

• Austria

International Drug Name Search

Nitrofurazona Sertex

Nitrofurazona Sertex may be available in the countries listed below.

Ingredient matches for Nitrofurazona Sertex

Nitrofural

Nitrofural is reported as an ingredient of Nitrofurazona Sertex in the following countries:

• Argentina

International Drug Name Search

Beatizem

Beatizem may be available in the countries listed below.

Ingredient matches for Beatizem

Diltiazem

Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Beatizem in the following countries:

• Singapore

International Drug Name Search

Tetryzolin DMP

Tetryzolin DMP may be available in the countries listed below.

Ingredient matches for Tetryzolin DMP

Tetryzoline

Tetryzoline hydrochloride (a derivative of Tetryzoline) is reported as an ingredient of Tetryzolin DMP in the following countries:

• Germany

International Drug Name Search

Neuralprona

Neuralprona may be available in the countries listed below.

Ingredient matches for Neuralprona

Naproxen

Naproxen is reported as an ingredient of Neuralprona in the following countries:

• Argentina

International Drug Name Search

Fenazopiridina UQP

Fenazopiridina UQP may be available in the countries listed below.

Ingredient matches for Fenazopiridina UQP

Phenazopyridine

Phenazopyridine is reported as an ingredient of Fenazopiridina UQP in the following countries:

• Peru

International Drug Name Search

Fosinopril-Natrium / HCT Actavis

Fosinopril-Natrium/HCT Actavis may be available in the countries listed below.

Ingredient matches for Fosinopril-Natrium/HCT Actavis

Fosinopril

Fosinopril sodium salt (a derivative of Fosinopril) is reported as an ingredient of Fosinopril-Natrium/HCT Actavis in the following countries:

• Austria

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Fosinopril-Natrium/HCT Actavis in the following countries:

• Austria

International Drug Name Search

Dexamethasone eent

Class: Corticosteroids
ATC Class: S01CA01
VA Class: OP350
CAS Number: 50-02-2
Brands: Ciprodex, Maxidex, Maxitrol, TobraDex

Introduction

A synthetic fluorinated corticosteroid.^{a b d}

Uses for Dexamethasone

Ophthalmic Inflammation

Symptomatic relief of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe (e.g., allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides).^{a c d e f g h}

Treatment of chronic anterior uveitis.^{e g h}

Treatment of corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.^{a c d e f g h}

Bacterial Ophthalmic Infections

Used for anti-inflammatory properties in conjunction with appropriate anti-infective therapy in some bacterial infections of the eye;^{e f g h} used in fixed combination with neomycin and polymyxin B sulfates or tobramycin when such combination therapy is indicated.^{e f g h} If an ophthalmic corticosteroid is used in combination with an ophthalmic anti-infective, weigh benefits against risks.^d (See Infections under Cautions.)

Otic Inflammation

Symptomatic relief of corticosteroid-responsive inflammatory conditions of the ear canal (e.g., allergic otitis externa).^{b c i}

Bacterial Otic Infections

Used for anti-inflammatory properties in conjunction with ciprofloxacin for treatment of acute otitis externa and in pediatric patients with tympanostomy tubes for acute otitis media.ⁱ

Used to reduce edema and inflammation in select cases of purulent and nonpurulent infective otitis externa.^c

If a corticosteroid is used alone or in combination with an otic anti-infective, weigh benefits against risks.^d (See Infections under Cautions.)

Dexamethasone Dosage and Administration

Administration

Apply topically to the eye or ear.^{a b c e f g h i}

Ophthalmic Administration

Apply topically to the eye as an ophthalmic ointment, solution, or suspension.^{a b c e f g h}

Not for injection.^{e f g h}

Shake suspension well prior to each use.^{a g}

Avoid contamination of preparation container.^{a b e f}

Do not administer solutions or suspensions containing benzalkonium chloride while wearing soft contact lenses.^{a c g} Wait ≥15 minutes after instilling drops before inserting contact lenses.^c (See Advice to Patients.)

Otic Administration

Apply topically to the ear as an otic suspension or an ophthalmic solution.^{b c i}

Not for injection.ⁱ Do not instill otic preparations into the eye.ⁱ

May use dexamethasone sodium phosphate ophthalmic solution in the ear.^{b c}

Shake suspension well prior to each use.ⁱ

To avoid dizziness that may result from instilling a cold preparation into the ear, warm the preparation by holding the bottle in the hands for 1–2 minutes prior to administration.ⁱ

Clean and dry ear canal prior to administration;^{b c d} pH of otic preparations should be neutral or acidic.^b

Lie with the affected ear upward and instill drops.ⁱ For pediatric patients with otitis media and tympanostomy tubes, pump the tragus 5 times to ease penetration of drops into the middle ear.ⁱ For acute otitis externa, pull outer ear lobe upward and backward to facilitate entry of drug into ear canal.ⁱ

Keep affected ear upward for ≥60 seconds following drug administration.ⁱ If necessary, repeat procedure for the opposite ear.ⁱ

Use otic corticosteroids sparingly to prevent an accumulation of excess debris in the ear canal.^{b d}

Dosage

Commercially available alone or in fixed combination with anti-infectives; available as dexamethasone or dexamethasone sodium phosphate.^{a c d e f g h i} Solution available as dexamethasone sodium phosphate; dosage expressed in terms of dexamethasone phosphate.^c

Pediatric Patients

Bacterial Ophthalmic Infections

Duration of therapy depends on the type and severity of the disease and response to therapy.^g Do not discontinue prematurely.^g

When discontinuing therapy, gradually taper dosing frequency to avoid exacerbation of the disease.^b

Dexamethasone 0.1% and Tobramycin 0.3%

Ophthalmic Suspension

Children ≥2 years of age: Initial 24–48 hours, 1 or 2 drop(s) into the conjunctival sac of the affected eye(s) every 2 hours.^g Thereafter, 1 or 2 drops every 4–6 hours.^g Gradually reduce dosing frequency as infection improves.^g

Ophthalmic Ointment

Children ≥2 years of age: Apply a 1.25-cm ribbon into the conjunctival sac of the affected eye(s) up to 3 or 4 times daily.^h

Bacterial Otic Infections

Acute Otitis Externa

Otic Suspension (Dexamethasone 0.1% and Ciprofloxacin 0.3%)

Children ≥6 months of age: 4 drops into the affected ear(s) twice daily for 7 days.ⁱ

Acute Otitis Media

Otic Suspension (Dexamethasone 0.1% and Ciprofloxacin 0.3%)

Children ≥6 months of age with tympanostomy tubes: 4 drops into the affected ear(s) twice daily for 7 days.ⁱ

Adults

Ophthalmic Inflammation and Bacterial Infections

Duration of therapy depends on the type and severity of the disease and response to therapy.^g Do not discontinue prematurely.^g

When discontinuing therapy, gradually taper dosing frequency to avoid exacerbation of the disease.^b

Dexamethasone 0.1%

Ophthalmic Suspension

For mild inflammation: 1 or 2 drops into the conjunctival sac of the affected eye(s) up to 4–6 times daily.^a

For severe inflammation: 1 or 2 drops into the conjunctival sac of the affected eye(s) every hour.^a Taper dosing frequency as inflammation subsides.^a

Dexamethasone Sodium Phosphate 0.1%

Ophthalmic Solution

Initially, 1 or 2 drops into the conjunctival sac of the affected eye(s) every hour during the day and every 2 hours during the night.^c When a favorable response is attained, decrease to 1 drop every 4 hours.^c May decrease to 1 drop 3 or 4 times daily to control symptoms.^c

Dexamethasone 0.1%, Neomycin 0.35%, and Polymyxin B Sulfates 10,000 units

Ophthalmic Suspension

For mild inflammation: 1 or 2 drop(s) into the conjunctival sac of the affected eye(s) up to 4–6 times daily.^f

For severe inflammation: 1 or 2 drops into the conjunctival sac of the affected eye(s) hourly.^f As inflammation subsides, gradually reduce dosing frequency to discontinue.^f

Ophthalmic Ointment

Apply a 1.25-cm ribbon into the conjunctival sac of the affected eye(s) up to 3 or 4 times daily.^e

Dexamethasone 0.1% and Tobramycin 0.3%

Ophthalmic Suspension

Initial 24–48 hours, 1 or 2 drops into the conjunctival sac of the affected eye(s) every 2 hours; thereafter, 1 or 2 drops every 4 to 6 hours.^g Gradually reduce dosing frequency as infection improves.^g

Ophthalmic Ointment

Apply a 1.25-cm ribbon into the conjunctival sac of the affected eye(s) up to 3 or 4 times daily.^h

Otic Inflammation

Dexamethasone Sodium Phosphate 0.1% Ophthalmic Solution

Otic

Initially, 3 or 4 drops of the ophthalmic solution into the ear canal 2 or 3 times daily.^{b c} May reduce dosing frequency as symptoms improve.^{b c} Gradually taper the drug when it is discontinued.^c

Alternatively, a cotton wick saturated with the ophthalmic solution may be packed into the ear canal; keep the wick moist with the ophthalmic solution; remove saturated wick from ear after 12 to 24 hours.^{b c} Repeat as necessary.^{b c}

Duration of treatment may range from a few days to several weeks.^b

Bacterial Otic Infections: Acute Otitis Externa

Dexamethasone 0.1% and Ciprofloxacin 0.3%

Otic

4 drops into the affected ear(s) twice daily for 7 days.ⁱ

Special Populations

No special population dosage recommendations at this time.^{a c e f g h i}

Cautions for Dexamethasone

Contraindications

• 
  

  Known hypersensitivity to dexamethasone or any ingredient in the formulation.^{a c e f g h i}

  
  

• Ophthalmic Preparations


• 
  

  Viral diseases of the cornea and conjunctiva (e.g., epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella).^{a c e f g h}

  
  


• 
  

  Mycobacterial infection (e.g., ocular tuberculosis) of the eye.^{a c e f g h}

  
  


• 
  

  Fungal disease of ocular structures.^{a c e f g h}

  
  

• Otic Preparations


• 
  

  Viral infections of the external ear canal (e.g., herpes simplex).ⁱ

  
  


• 
  

  Perforation of the ear drum.^c

  
  


• 
  

  Fungal diseases of auricular structures.^c

  
  

Warnings/Precautions

Warnings

Ocular Effects

Risk of glaucoma with possible damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation with prolonged use of corticosteroids.^{a c d e f g h} Use with caution in patients with glaucoma because IOP may increase.^{a c d e f g h}

If used for ≥10 days, monitor IOP routinely even though monitoring may be difficult in children and uncooperative patients.^{a c d e f g h}

In conditions causing thinning of the cornea or sclera, perforations reported with use of topical corticosteroids.^{a c d e f g h}

Use of high-dose corticosteroids may delay healing.^{c h} Use after cataract surgery may delay healing and increase incidence of bleb formation.^c

Infections

Prolonged use may suppress the host response and thus increase the risk of secondary ocular infections.^{a c e f g}

In acute purulent conditions of the eye or ear, corticosteroids may mask infection or enhance existing infection.^{a c d e f g h} (See Contraindications under Cautions.)

Herpes Simplex

Use of corticosteroids in the treatment of herpes simplex infections other than epithelial herpes simplex keratitis, in which corticosteroids are contraindicated, requires great caution; periodic slit-lamp microscopy is essential.^{a c e f}

General Precautions

Evaluation of Ocular Condition

Initial prescription or renewal of medication order beyond 8 g of 0.1% ointment or 20 mL of 0.1% suspension should be provided only after examination of the patient with the aid of magnification (e.g., slit lamp biomicroscopy, fluorescein staining where appropriate).^{e f g h}

Fungal Infections

Long-term local corticosteroid application associated with development of fungal infections of the cornea.^{a d e f g h} Consider possibility of fungal infection in patients with persistent corneal ulceration who have been or are receiving corticosteroid therapy.^{a c d e f h}

Corneal Reepithelialization

Use of ophthalmic ointments may decrease rate of corneal reepithelialization.^h

Use of Fixed Combination

When used in fixed combination with ciprofloxacin, neomycin and polymyxin B sulfates, or tobramycin, consider the cautions, precautions, and contraindications associated with the concomitant agents.^{e f g h i}

Specific Populations

Pregnancy

Category C.^{a c e f g h i}

Lactation

Not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in milk.^{a e f g h i}

Caution if used in nursing women.^{a e f g h}

Dexamethasone sodium phosphate ophthalmic solution and dexamethasone in fixed combination with ciprofloxacin otic suspension: Manufacturers recommend discontinuing nursing or the drug.^{c i}

Pediatric Use

Safety and efficacy of ophthalmic dexamethasone suspension or dexamethasone sodium phosphate solution not established.^{a c}

Safety and efficacy of ophthalmic dexamethasone in fixed combination with neomycin and polymyxin B sulfates not established.^{e f}

Safety and efficacy of ophthalmic dexamethasone in fixed combination with tobramycin not established in children <2 years of age.^{g h}

Safety and efficacy of otic dexamethasone suspension in fixed combination with ciprofloxacin not established in infants <6 months of age.ⁱ

Geriatric Use

No substantial differences in safety or efficacy relative to younger patients.^{a e h}

Common Adverse Effects

Ophthalmic administration: Elevated IOP,^{a c e f g h} posterior subcapsular cataract formation,^{a c e g h} optic nerve damage,^{a c e f g h} delayed wound healing.^{e f h}

Otic administration: Ear discomfort, ear pain, ear pruritus.ⁱ

Dexamethasone Pharmacokinetics

Absorption

Bioavailability

Corticosteroids are absorbed through the aqueous humor; because only low doses are given, little if any systemic absorption occurs after ophthalmic administration.^d

Distribution

Extent

Systemically absorbed corticosteroids are distributed into milk; not known whether topical corticosteroids could produce detectable levels in human milk.^{a e f g h i}

Stability

Storage

Ophthalmic

Ointment

Neomycin and polymyxin B sulfates and dexamethasone: 2–25°C.^e

Tobramycin and dexamethasone: 8–27°C.^h

Solution

Dexamethasone sodium phosphate: 15–30°C.^c

Suspension

Dexamethasone: Tight, light-resistant containers^b at 8–27°C;^a store upright.^a

Neomycin and polymyxin B sulfates and dexamethasone: 8–27°C.^f

Tobramycin and dexamethasone: Upright containers at 8–27°C.^g

Otic

Suspension

Ciprofloxacin and dexamethasone: 15–30°C; protect from light.ⁱ Do not freeze.ⁱ

ActionsActions

• 
  

  Corticosteroids suppress the inflammatory response to mechanical, chemical, or immunologic agents.^{a c d e f g h}

  
  


• 
  

  Corticosteroids inhibit edema, fibrin deposition, capillary dilation, leukocyte and phagocyte migration; in addition, the drugs reduce capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.^d

  
  

Advice to Patients

• 
  

  Importance of removing soft contact lenses prior to administering preparations containing benzalkonium chloride^{a g h} and of delaying reinsertion of the lenses for ≥15 minutes after administration.^c Importance of not wearing contact lenses if signs or symptoms of an eye infection occur.^e

  
  


• 
  

  Importance of learning and adhering to proper administration techniques to avoid contamination of the tip of the container.^{a e f i}

  
  


• 
  

  Importance of advising patients not to touch tip of dropper to eye or surrounding tissue.^{a c f g h i}

  
  


• 
  

  Importance of informing a clinician if another eye condition (e.g., trauma, surgery, infection) develops during ophthalmic therapy.^c

  
  


• 
  

  Advise patients to warm the ear suspension by holding the bottle in the hands for 1–2 minutes prior to administration.ⁱ

  
  


• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.^{a c e g h i}

  
  


• 
  

  Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.^{a c e g h i}

  
  


• 
  

  Importance of informing patients of other important precautionary information. (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Dexamethasone

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Ophthalmic	Suspension	0.1%	Maxidex (with benzalkonium chloride; viscous)	Alcon

Ciprofloxacin and Dexamethasone

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Otic	Suspension	Ciprofloxacin 0.3% and Dexamethasone 0.1% per mL	Ciprodex (with benzalkonium chloride)	Alcon

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Neomycin and Polymyxin B Sulfates and Dexamethasone

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Ophthalmic	Ointment	Neomycin Sulfate 0.35% (of neomycin), Polymyxin B Sulfate 10,000 units (of polymyxin B) and Dexamethasone 0.1% per g*	Maxitrol	Alcon
			Neomycin and Polymyxin B Sulfates and Dexamethasone	Bausch & Lomb, Falcon, Fougera
	Suspension	Neomycin Sulfate 0.35% (of neomycin), Polymyxin B Sulfate 10,000 units (of polymyxin B) and Dexamethasone 0.1% per mL*	Maxitrol (with benzalkonium chloride; viscous)	Alcon
			Neomycin and Polymyxin B Sulfates and Dexamethasone	Bausch & Lomb, Falcon

Tobramycin and Dexamethasone

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Ophthalmic	Ointment	0.3% Tobramycin and Dexamethasone 0.1% per g	TobraDex (with chlorobutanol)	Alcon
	Suspension	0.3% Tobramycin and Dexamethasone 0.1% per mL	TobraDex (with benzalkonium chloride)	Alcon

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Dexamethasone Sodium Phosphate

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Ophthalmic	Solution	0.1% (of dexamethasone phosphate)*	Dexamethasone Sodium Phosphate (with benzalkonium chloride)	Falcon

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Ciprodex 0.3-0.1% Suspension (ALCON VISION): 7/$142.98 or 22/$407.95

Dexamethasone Sodium Phosphate 0.1% Solution (FALCON PHARMACEUTICALS): 5/$19.99 or 10/$30.97

Maxidex 0.1% Suspension (ALCON VISION): 5/$56.27 or 15/$154.48

TobraDex 0.3-0.1% Ointment (ALCON VISION): 3/$139.99 or 10/$400.95

TobraDex 0.3-0.1% Suspension (ALCON VISION): 5/$112.99 or 15/$320.96

TobraDex 0.3-0.1% Suspension (ALCON VISION): 2/$61.99 or 7/$159.97

Tobramycin-Dexamethasone 0.3-0.1% Suspension (FALCON PHARMACEUTICALS): 10/$129.98 or 30/$359.96

Tobramycin-Dexamethasone 0.3-0.1% Suspension (FALCON PHARMACEUTICALS): 5/$69.99 or 15/$179.98

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions April 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

a. Alcon Laboratories, Inc. Maxidex 0.1% (dexamethasone ophthalmic suspension) prescribing information. Fort Worth, TX; 2007 May.

b. AHFS drug information 2008. McEvoy GK, ed. Dexamethasone. Bethesda, MD: American Society of Health-System Pharmacists; 2008: 2874-5.

c. Falcon Pharmaceuticals. Dexamethasone sodium phosphate ophthalmic solution, USP prescribing information. Fort Worth, TX; 2007 Jul.

d. AHFS drug information 2008. McEvoy GK, ed. EENT corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2008: 2867-9.

e. Alcon Laboratories, Inc. Maxitrol(neomycin and polymyxin B sulfates, and dexamethasone ophthalmic ointment) prescribing information. Fort Worth, TX; 2003 Oct.

f. Alcon Laboratories, Inc. Maxitrol (neomycin and polymyxin B sulfates, and dexamethasone ophthalmic suspension) prescribing information. Fort Worth, TX; 2003 Aug.

g. Alcon Laboratories, Inc. TobraDex (tobramycin and dexamethasone ophthalmic suspension) prescribing information. Fort Worth, TX; 2006 May.

h. Alcon Laboratories, Inc. TobraDex (tobramycin and dexamethasone ophthalmic ointment) prescribing information. Fort Worth, TX; 2003 Oct.

i. Alcon Laboratories, Inc. Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1% sterile otic suspension) prescribing information. Fort Worth, TX; 2003 Jul.

Gammar

Gammar may be available in the countries listed below.

Ingredient matches for Gammar

Aminobutyric Acid, þ-

Aminobutyric Acid, þ- is reported as an ingredient of Gammar in the following countries:

• Brazil

International Drug Name Search

Klinoksin

Klinoksin may be available in the countries listed below.

Ingredient matches for Klinoksin

Clindamycin

Clindamycin dihydrogen phosphate (a derivative of Clindamycin) is reported as an ingredient of Klinoksin in the following countries:

• Turkey

Clindamycin hydrochloride (a derivative of Clindamycin) is reported as an ingredient of Klinoksin in the following countries:

• Turkey

International Drug Name Search

Anprotiazolo

Anprotiazolo may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Anprotiazolo

Formosulfathiazole

Formosulfathiazole is reported as an ingredient of Anprotiazolo in the following countries:

• Italy

International Drug Name Search

Renitec

Renitec may be available in the countries listed below.

Ingredient matches for Renitec

Enalapril

Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Renitec in the following countries:

• Algeria


• Argentina


• Aruba


• Australia


• Austria


• Bahamas


• Barbados


• Belgium


• Belize


• Brazil


• Bulgaria


• Cayman Islands


• China


• Colombia


• Czech Republic


• Dominican Republic


• Ecuador


• Estonia


• Ethiopia


• Finland


• France


• Georgia


• Greece


• Hong Kong


• Hungary


• Jamaica


• Luxembourg


• Malaysia


• Mexico


• Netherlands


• Netherlands Antilles


• New Zealand


• Norway


• Oman


• Peru


• Philippines


• Portugal


• Romania


• Russian Federation


• Singapore


• Slovakia


• South Africa


• Spain


• Sri Lanka


• Sweden


• Taiwan


• Thailand


• Trinidad & Tobago


• Turkey


• Venezuela


• Vietnam

International Drug Name Search